Platform & Strategies

Publications

HomePlatform & StrategiesPublications

논문 검색 폼 search
게시물 목록(NO,Pipeline,Journal,Date,Title,Link,PDF)
NO Pipeline Journal Date Title Link PDF
12 ABL503 Clinical Cancer Reserach 2024 Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade 링크정보 아이콘 PDF 아이콘
11 ABL111 JITC 2023 CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor- directed T-cell activation 링크정보 아이콘 PDF 아이콘
10 General (ABL001) Mol Cancer Ther. 2023 Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development 링크정보 아이콘 PDF 아이콘
9 ABL301 Cell Rep Methods 2022 Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier 링크정보 아이콘 PDF 아이콘
8 ABL501 Molecular Therapy 2022 LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation 링크정보 아이콘 PDF 아이콘
7 General Vaccines 2021 Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies 링크정보 아이콘 PDF 아이콘
6 ADC (Nterm) mAbs 2021 N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability 링크정보 아이콘 PDF 아이콘
5 ABL503 JITC 2021 Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade 링크정보 아이콘 PDF 아이콘
4 4-1BB Platform Science Advances 2021 B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+tumor-infiltrating lymphocytes 링크정보 아이콘 PDF 아이콘
3 ABL001 BMB Reports 2020 Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer 링크정보 아이콘 PDF 아이콘
    • Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

      2024 링크정보 아이콘 PDF 아이콘

    • CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor- directed T-cell activation

      2023 링크정보 아이콘 PDF 아이콘

    • Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development

      2023 링크정보 아이콘 PDF 아이콘

    • Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier

      2022 링크정보 아이콘 PDF 아이콘

    • LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

      2022 링크정보 아이콘 PDF 아이콘

    • Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

      2021 링크정보 아이콘 PDF 아이콘

    • N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability

      2021 링크정보 아이콘 PDF 아이콘

    • Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

      2021 링크정보 아이콘 PDF 아이콘

    • B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+tumor-infiltrating lymphocytes

      2021 링크정보 아이콘 PDF 아이콘

    • Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer

      2020 링크정보 아이콘 PDF 아이콘

12다음페이지로마지막페이지로